[P006] Poster

1:00 PM - 1:50 PM JST(4:00 AM - 4:50 AM UTC)

[P03-426] A Scalable 3D Mold-Based Platform for Uniform BO–VO–GBM Fusion Organoids and Drug Evaluation

○Taehyeong Ha¹, Kihwan Hwang^1,2 (1. SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL (Korea), 2. Seoul National University College of Medicine (Korea))

Keywords:

Glioblastoma (GBM),Fusion Organoids,3D Mold-Based Platform,Drug Screening

Glioblastoma (GBM) is the most common malignant brain tumor of the central nervous system and is associated with a poor median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a physiologically relevant human microenvironment and the inability to reproducibly model tumor heterogeneity and cell–cell interactions.To address these limitations, we developed a scalable platform for generating uniform BO–VO–GBM fusion organoids using a 3D mold-based system. This approach enables controlled assembly of brain organoids (BOs), vascular organoids (VOs), and patient-derived GBM tissues with high reproducibility and structural consistency.Compared to conventional spontaneous fusion methods, our platform allows faster and more reliable formation of fusion organoids. The resulting assembloids exhibit stable integration between tumor, neural, and vascular components, supporting complex multicellular interactions within a defined microenvironment. Importantly, this system enables functional drug evaluation in a reproducible and physiologically relevant setting. Treatment responses to therapeutic agents resulted in measurable changes in tumor growth and structural organization, demonstrating its applicability for drug screening.Overall, our 3D mold-based fusion organoid platform provides a robust and reproducible method for modeling GBM in a human-relevant context and offers a promising tool for therapeutic evaluation and precision medicine.